Literature DB >> 25467641

Added value of one-view breast tomosynthesis combined with digital mammography according to reader experience.

Isabelle Thomassin-Naggara1, Nicolas Perrot2, Sophie Dechoux3, Carine Ribeiro4, Jocelyne Chopier5, Cedric de Bazelaire6.   

Abstract

PURPOSE: To retrospectively evaluate the added value of one-view breast tomosynthesis in adjunct with mammography to characterize breast lesions.
MATERIALS AND METHODS: Our institutional ethics committees approved the study and granted a waiver of informed consent. One hundred fifty-five women (mean age, 51.3 years, range: 24-92 years) who systematically underwent mammography and breast tomosynthesis with subsequent percutaneous biopsy were analyzed. Four radiologists (two seniors, R1 and R2, and two juniors, R3 and R4 with 30, 10, 3 and 1 years of experience in breast imaging, respectively) independently reviewed exams in two steps: mammography alone and tomosynthesis in adjunct with mammography. The lesions in the cohort included 39.3% (61/155) cancers, 2.5% (4/155) high-risk lesions and 58.1% (90/155) benign lesions. A receiver operating characteristic (ROC) curve analysis was performed to compare the results of the two readings.
RESULTS: There was almost perfect agreement irrespective of reader experience for the reading of the mammography in adjunct with tomosynthesis, whereas agreement was poor between junior and senior readers for the reading of mammography alone. Area under the ROC (Az) values for the tomosynthesis in adjunct with mammography were significantly better than Az values for mammography alone for all readers except the most experienced, for whom only a tendency was noted. The proportion of cancers undiagnosed by mammography alone that were well diagnosed by tomosynthesis in adjunct with mammography was 6.5% (4/61), 13.1% (8/61), 27.8% (17/61) and 26.2% (16/61) for Readers 1, 2, 3 and 4, respectively. The proportion of false positive cases induced by the addition of breast tomosynthesis to mammography was 2.1% (2/94), 2.1% (2/94), 9.5% (9/94) and 12.7% (12/94) for Readers 1, 2, 3 and 4, respectively.
CONCLUSION: Adding breast tomosynthesis to mammography improved sensitivity and negative predictive value for all readers except for the most experienced one, in whom only a tendency for improvement was noted.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast tomosynthesis; Cancer; Diagnosis; Mammography

Mesh:

Year:  2014        PMID: 25467641     DOI: 10.1016/j.ejrad.2014.10.022

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  Imaging features and conspicuity of invasive lobular carcinomas on digital breast tomosynthesis.

Authors:  Foucauld Chamming's; Ellen Kao; Ann Aldis; Romuald Ferré; Atilla Omeroglu; Caroline Reinhold; Benoit Mesurolle
Journal:  Br J Radiol       Date:  2017-04-03       Impact factor: 3.039

Review 2.  Review of radiation dose estimates in digital breast tomosynthesis relative to those in two-view full-field digital mammography.

Authors:  T M Svahn; N Houssami; I Sechopoulos; S Mattsson
Journal:  Breast       Date:  2014-12-29       Impact factor: 4.380

3.  Characterization of Breast Masses in Digital Breast Tomosynthesis and Digital Mammograms: An Observer Performance Study.

Authors:  Heang-Ping Chan; Mark A Helvie; Lubomir Hadjiiski; Deborah O Jeffries; Katherine A Klein; Colleen H Neal; Mitra Noroozian; Chintana Paramagul; Marilyn A Roubidoux
Journal:  Acad Radiol       Date:  2017-06-21       Impact factor: 3.173

Review 4.  Strategies to Increase Cancer Detection: Review of True-Positive and False-Negative Results at Digital Breast Tomosynthesis Screening.

Authors:  Katrina E Korhonen; Susan P Weinstein; Elizabeth S McDonald; Emily F Conant
Journal:  Radiographics       Date:  2016-10-07       Impact factor: 5.333

Review 5.  The role of digital breast tomosynthesis in breast cancer screening: a manufacturer- and metrics-specific analysis.

Authors:  A Hadjipanteli; M Kontos; A Constantinidou
Journal:  Cancer Manag Res       Date:  2019-10-31       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.